Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Immunic, Inc.NASDAQ: IMUX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $33.2M rose 23.8% year over year, ahead of the +8.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 42.3% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +23.8% holds above the trailing-twelve-month pace of +8.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 103.23M USD
- Year-over-year change
- +5.3%
- 4-year CAGR
- +3.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 103.23M | +5.3% |
| FY2024 | 2024-12-31 | 98.05M | -1.2% |
| FY2023 | 2023-12-31 | 99.22M | -17.0% |
| FY2022 | 2022-12-31 | 119.49M | +30.4% |
| FY2021 | 2021-12-31 | 91.67M | — |
Operating Expenses vs competitors
How IMUX compares with its peers on the latest reported figures
- IMUX's LTM Mar 2026 operating expenses of $109.61M is the 4th highest of the 9 companies compared; the peer median is $83.09M.
- Its year-over-year change of +8.6% is the 2nd highest of 9, against a peer median of -11.0%.
- Over three fiscal years its annual growth of -4.8% compares with a peer median of +13.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $217.43M | +108.0% | +24.1% | 85.1% | |
| LTM Mar 2026 | $137.15M | -4.8% | +21.4% | 1501.1% | |
| LTM Mar 2026 | $112.46M | -11.2% | +5.9% | — | |
| LTM Mar 2026 | $109.61M | +8.6% | -4.8% | — | |
| LTM Mar 2026 | $83.6M | -5.5% | +4.1% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $82.58M | -10.8% | +36.3% | — |
| LTM Mar 2026 | $65.98M | -50.3% | -1.5% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $62.05M | -76.5% | +45.9% | 1447.8% |
| LTM Mar 2026 | $60.34M | -23.7% | -28.4% | — | |
| Peer median (excluding IMUX) | $83.09M | -11.0% | +13.6% | 1447.8% | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 61.12M | 71.26M | 83.22M | 80.05M | 81.98M |
| Selling, General & Admin | 13.3M | 15.26M | 16.01M | 18.01M | 21.25M |
| Operating Expenses | 91.67M | 119.49M | 99.22M | 98.05M | 103.23M |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| EBITDA | (92.86M) | (86.44M) | (93.5M) | (100.37M) | (97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (91.67M) | (119.49M) | (99.22M) | (98.05M) | (103.23M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 66K | 1.04M | 3.08M | 3.39M | 1.04M |
| Interest Expense | 0 | 1.04M | 0 | 0 | 0 |
| Other Income / Expenses | (1.28M) | (919K) | 5.61M | (2.46M) | 6.06M |
| Income Before Tax | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| EPS (Diluted) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| Weighted Avg Shares | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
| Weighted Avg Shares (Diluted) | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.